Analysts expect Zai Lab Limited (NASDAQ:ZLAB – Get Rating) to report $53.83 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Zai Lab’s earnings. The lowest sales estimate is $49.50 million and the highest is $57.50 million. Zai Lab posted sales of $36.94 million during the same quarter last year, which would suggest a positive year over year growth rate of 45.7%. The business is expected to report its next earnings results on Monday, January 1st.
According to Zacks, analysts expect that Zai Lab will report full year sales of $235.81 million for the current year, with estimates ranging from $211.80 million to $249.50 million. For the next financial year, analysts anticipate that the firm will report sales of $436.32 million, with estimates ranging from $336.30 million to $544.65 million. Zacks’ sales calculations are an average based on a survey of research firms that cover Zai Lab.
ZLAB has been the topic of a number of recent analyst reports. SVB Leerink dropped their price target on Zai Lab from $102.00 to $101.00 and set an “outperform” rating on the stock in a report on Thursday, April 21st. Citigroup reduced their target price on Zai Lab from $198.00 to $193.00 in a research report on Thursday, May 12th. JPMorgan Chase & Co. cut their price objective on Zai Lab from $136.00 to $112.00 and set an “overweight” rating for the company in a report on Monday, April 4th. Finally, Zacks Investment Research raised Zai Lab from a “sell” rating to a “hold” rating in a research report on Thursday, April 7th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $117.50.
Shares of ZLAB opened at $29.43 on Thursday. Zai Lab has a 1 year low of $24.50 and a 1 year high of $179.28. The business has a 50-day moving average of $37.18 and a 200-day moving average of $48.66. The company has a market capitalization of $2.88 billion, a price-to-earnings ratio of -5.01 and a beta of 1.22.
Zai Lab Company Profile (Get Rating)
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors.
- Get a free copy of the StockNews.com research report on Zai Lab (ZLAB)
- Stratasys Stock Forming a Tradeable Bottom
- It’s Time To Get Interested In Ethereum Again
- How to Invest in Water Stocks: A Tutorial for Investors
- Expedia Group: Recovering with the Travel Industry
- It’s Time To Grab The Lovesac Company By The Shorts
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.